Last reviewed · How we verify

Insulin glargine U100 — Competitive Intelligence Brief

Insulin glargine U100 (Insulin glargine U100) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting basal insulin. Area: Diabetes.

marketed Long-acting basal insulin Insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Insulin glargine U100 (Insulin glargine U100) — Novo Nordisk A/S. Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Insulin glargine U100 TARGET Insulin glargine U100 Novo Nordisk A/S marketed Long-acting basal insulin Insulin receptor
Tresiba INSULIN DEGLUDEC Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2015-01-01
Levemir INSULIN DETEMIR Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2005-01-01
Apidra INSULIN GLULISINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2004-01-01
Novolog INSULIN ASPART Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Lantus INSULIN GLARGINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Humalog INSULIN LISPRO Eli Lilly marketed Insulin Analog [EPC] Insulin receptor 1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting basal insulin class)

  1. Sanofi · 12 drugs in this class
  2. Novo Nordisk A/S · 3 drugs in this class
  3. Life for a Child Program, Diabetes Australia · 1 drug in this class
  4. Massachusetts General Hospital · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Providence Health & Services · 1 drug in this class
  7. Rabin Medical Center · 1 drug in this class
  8. Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 drug in this class
  9. University Hospital Tuebingen · 1 drug in this class
  10. Gan and Lee Pharmaceuticals, USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin glargine U100 — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-u100. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: